



Yale SCHOOL OF  
MANAGEMENT

# Insurer (In)Efficiency in the Medicare Part D Program

Kate Ho, Columbia University & NBER

Joseph Hogan, Columbia University

Fiona Scott Morton, Yale University & NBER

EARIE 2013



Yale SCHOOL OF  
MANAGEMENT

# Part D Basics

- Medicare created in 1965 and now insures 43+ million elderly and disabled in US (Medicaid insures the poor.)
  - Part A: hospital inpatient care and some long term care
  - Part B: hospital outpatient care and physician services
  - Part C: Medicare HMO
- For first 40 yrs –prescription drug expenses uncovered
  - Certain physician-administered drugs the exception
- Changed in Jan 2006 with enactment of Medicare Part D which created prescription drug insurance for the elderly
  - Largest expansion of Medicare since its inception
  - Projected to cost \$780 billion in first ten years (2006-15)



Yale SCHOOL OF  
MANAGEMENT

# Novel

- **Privatized**
  - New example of procurement mechanism; private insurance plans compete for enrollees
  - Plans are 75% subsidized by the government
  - Government does not set/bargain for pharmaceutical prices, instead plans contract with manufacturers.
  - Government does not set/bargain for plan premiums; only approves plans that conform to the regulations.
- **Complex**
  - Out-of-pocket costs are a non-linear function of RX spending
  - Formularies and rules limiting access to drugs differ across PDPs
  - Prices of the drugs on the formulary are choice of PDP and also vary
  - Government allows some flexibility in benefit design (though actuarially equivalent)



Yale SCHOOL OF  
MANAGEMENT


# Consumer's problem

- Consumer chooses among plans in region: 27+
  - Sponsor (e.g. Humana, United Healthcare, union)
  - Standard Plan or Enhanced Plan (more benefits)
  - Schedule of out of pocket payments: “actuarially equivalent” means can vary
- Formulary
  - Different plans may have different preferred brands, prior authorization, step therapy. PDP must cover 2 drugs per therapeutic class.
  - Co-payments therefore vary across plans for same medication
- Prices
  - Expected cost = annual premium + expected out-of-pocket payments
  - Search plans for lowest prices on drugs *currently* taking and *expect* will take next year
- Other: quality, service, brand, pharmacy network



Yale School of  
Management

Figure 1: Out-of-Pocket Spending in 2006 for Medicare Part D Recipients





# Plan's problem

- **Insurers design plans**
  - Must offer a basic plan if want to offer an enhanced plan; which regions?
  - Defined benefit, or alternative design that is actuarially equivalent?
  - Design formulary; choose schedule of co-payments; negotiate pharmacy network
- **Plans submit bids**
  - Calculate cost of running plan = bid = drug purchases, administration and profit, less federal subsidies
  - Government takes average bid and applies 75% subsidy.
    - This is “base beneficiary premium”
    - Actual premium for a plan is adjusted (up or down) by the full difference between that plan's own bid and the average bid
- **After prices set, compete for consumers**
  - Premiums lower than expected in 2006. Rising steadily since then.



Yale SCHOOL OF  
MANAGEMENT

# Entry

- Lots of Entry
  - 226 sponsors, 1678 PDPs, 2195 MA-PDs; 3873 region-plan combinations; at least 27 plans in each state-year
- Concentration initially high
  - Top two (UHG-Pacificare and Humana, Inc.) had 44% nationally; Next eight had 28%
  - Entry and exit fairly balanced 2007-9
  - 2010-11 significant exit
- Just 14% of enrollees choose standard benefit
  - 51% in actuarially equivalent and rest in enhanced plans



Yale SCHOOL OF  
MANAGEMENT

# Policy questions

- How well does this marketplace perform?
- Does the private provision of benefits generate lower prices and/or better quality and innovation than a standard government program?
  - Lower prices for drugs? (Duggan and Scott Morton)
  - Lower prices for insurance? (Ho, Hogan, and Scott Morton)
- Many other questions: innovation, doughnut hole, health outcomes, etc
- Skip previous literature in the interests of time
  - Part D; other privatized markets; consumer inattention





Yale SCHOOL OF  
MANAGEMENT

# Impact on price of drugs

- Part D should affect pharmaceutical manufacturer's profit-maximizing price
- Two key forces– theoretically ambiguous which dominates
  - More insurance => lower demand elasticity => higher price
    - Shown for Medicaid (Duggan and Scott Morton 2006)
  - Plans compare price/efficacy => negotiate discounts => lower price
    - Impact of the PBM function
- Net effect: prices fall (20+ %) for Part D consumers for drugs that face competition



Yale SCHOOL OF  
MANAGEMENT

# Impact on price of insurance

- Cost of treatments rising slowly 2.8%
- Cost of services rising slowly 2.4%
- Yet cost of insurance rising quickly
  - CBO – plan profits 8% p.a.
  - Our NJ data – premiums 17% p.a.
- It may be that program design is not maximizing competition among insurers



Yale SCHOOL OF  
MANAGEMENT

# ACA = Obamacare

- New law makes this analysis important
- Many Americans will choose a privately-provided, publicly-subsidized, healthcare plan starting in November 2013
- As with Part D, plans will compete for consumers



Yale SCHOOL OF  
MANAGEMENT

# Data

- Individual-level data from NJ
- Only enrollees in PDPs, only enrollees who pay full price
- 2006-2009: 4 years of data
- Detailed data: drugs purchased, payments made, demographics
- Sample each year and keep enrollees who stay in Part D (in PDP, no subsidy)



# Yale SCHOOL OF Counterfactual payments

## MANAGEMENT

- Critical for Part D research; we follow the literature (Abaluck-Gruber, Ketchum et al)
- Must calculate the cost to the consumer of enrolling in each alternate plans
- Calculate expected cost ex ante to avoid including unexpected health shocks
  - Chronic drugs: assume consumer foresees
  - Acute drugs: Place consumer in demographic/usage “bin”; take median expenditure on acute drugs
- Use prices and coverage rules of plan




Yale SCHOOL OF  
MANAGEMENT

# Policy Problem

- Next slide graphs the consumers' options over time
  - Optimal plan
  - Randomly chosen plan
  - Observed plan
  - Best plan within the sponsor's portfolio



# Figure 1





# Limited switching

**Table 4: Switching by Demographic Group**

	2006-07	2007-08	2008-09
<b>Whole Sample</b>	19.10%	24.10%	8.20%
<b>Female</b>	20.90%	26.30%	8.50%
<b>Non-White</b>	21.70%	26.90%	8.80%
<b>Income</b>	<b>2006-07</b>	<b>2007-08</b>	<b>2008-09</b>
<b>1st Quartile</b>	13.89%	18.38%	7.45%
<b>2nd Quartile</b>	18.08%	23.25%	8.21%
<b>3rd Quartile</b>	19.85%	24.72%	8.15%
<b>4th Quartile</b>	24.79%	30.68%	9.03%
<b>Age</b>	<b>2006-07</b>	<b>2007-08</b>	<b>2008-09</b>
<b>Under 65</b>	28.99%	33.10%	11.05%
<b>65-69</b>	12.61%	17.99%	7.69%
<b>70-74</b>	15.30%	20.63%	7.57%
<b>75-79</b>	17.53%	22.53%	7.42%
<b>80-84</b>	21.84%	26.26%	7.74%
<b>Over 85</b>	27.96%	34.21%	10.18%





# Significant overspending

**Table 5: Overspending by Part D Cohort**

	Full Sample			New Enrollees			2006 Enrollees		
	Count	\$ Error	% Error	Count	\$ Error	% Error	Count	\$ Error	% Error
<b>2006</b>	127,654	\$397.61 (\$361.80)	37.20 (22.39)	127,654	\$397.61 (\$361.80)	37.20 (22.39)	127,654	\$397.61 (\$361.80)	37.20 (22.39)
<b>2007</b>	141,897	\$320.55 (\$302.50)	29.63 (18.59)	28,460	\$300.23 (\$314.53)	30.21 (19.27)	113,437	\$325.65 (\$299.19)	29.49 (18.42)
<b>2008</b>	151,289	\$381.80 (\$350.77)	32.98 (17.96)	26,802	\$333.96 (\$348.95)	30.83 (18.90)	99,742	\$390.77 (\$348.06)	33.08 (17.47)
<b>2009</b>	159,906	\$436.96 (359.44)	36.01 (16.49)	31,275	\$371.78 (\$371.34)	32.02 (18.44)	84,258	\$459.19 (\$353.25)	37.01 (15.61)

Notes: Overspending (or error) by year. Standard deviations in parentheses.



Yale SCHOOL OF **Fraction within x% of optimal**  
MANAGEMENT

**Table 6B: Proportion Within X% of Optimal Spending**

<b>10%</b>	<b>Whole Sample</b>	<b>Switched Past Year</b>	<b>Didn't Switch</b>
<b>2006</b>	14.91%	-	-
<b>2007</b>	15.66%	15.04%	16.00%
<b>2008</b>	10.18%	17.28%	6.56%
<b>2009</b>	7.67%	27.81%	3.98%
<b>25%</b>	<b>Whole Sample</b>	<b>Switched Past Year</b>	<b>Didn't Switch</b>
<b>2006</b>	28.20%	-	-
<b>2007</b>	42.75%	49.94%	40.81%
<b>2008</b>	34.98%	43.15%	30.90%
<b>2009</b>	21.74%	46.99%	16.69%



Yale SCHOOL OF  
MANAGEMENT

# Response to own plan

- We have some work in the paper showing that consumers respond more to changes in their own plan
- They respond less to changes in other plans available in the marketplace
- Consumers appear to have asymmetric attention



Yale SCHOOL OF  
MANAGEMENT

# Why do consumers switch?

- Enrollees suffer from inattention; renew same plan
- A shock of some kind forces attention; attention leads to search
- Shocks we see in the data
  - Premium shock: current plan's premium rises (\$5+)
  - Coverage shock: current plan's coverage drops (6%)
  - Expenditure/health shock: expenditures absolutely high (top decile) and high for demographic group (80%+)



Yale SCHOOL OF  
MANAGEMENT

# Switching likelihood

	No shocks	All shocks	Premium and coverage	Acute and premium
2007	3.44%	72%	60%	22%
2008	4.81%	69%	52%	16%
2009	1.52%	34%	21%	14%
Overall	2.60%	60%	44%	19%



# No evidence of learning

Yale SCHOOL OF  
MANAGEMENT

**Table 13A: Overspending By Times Chosen**

Count	Once	Twice	Three Times	Four Times
2006	127,654	0	0	0
2007	120,257	21,640	0	0
2008	116,891	20,976	13,422	0
2009	131,167	18,007	7,748	2,984
% Error	Once	Twice	Three Times	Four Times
2006	37.20%	-	-	-
2007	29.92%	28.05%	-	-
2008	34.05%	29.57%	28.94%	-
2009	36.76%	33.94%	32.18%	25.55%
Within 10%	Once	Twice	Three Times	Four Times
2006	14.91%	-	-	-
2007	15.78%	15.04%	-	-
2008	8.30%	16.27%	17.05%	-
2009	6.21%	11.40%	14.60%	31.70%
Within 25%	Once	Twice	Three Times	Four Times
2006	28.20%	-	-	-
2007	41.46%	49.94%	-	-
2008	32.84%	42.52%	41.88%	-
2009	19.84%	26.91%	32.14%	47.32%



Yale SCHOOL OF

# Where do switchers go?

**Table 12: Next-Year Plan Choices and Overspending by Shock**

<b>2006</b>	<b>Acute Shock No Acute Shock</b>		<b>Premium Shock No Premium Shock</b>	
<b>% Pre-ICL Coverage</b>	69.83%	70.18%	70.90%	63.63%
<b>% ICL Coverage</b>	12.78%	12.07%	12.06%	12.93%
<b>Premium</b>	20.83	18.82	17.46	32.47
<b>% Within 25% of Optimal</b>	57.73%	49.06%	50.56%	44.62%
<b>2007</b>	<b>Acute Shock No Acute Shock</b>		<b>Premium Shock No Premium Shock</b>	
<b>% Pre-ICL Coverage</b>	72.42%	70.29%	69.82%	73.47%
<b>% ICL Coverage</b>	34.60%	28.73%	27.02%	39.21%
<b>Premium</b>	27.25	26.43	25.78	29.69
<b>% Within 25% of Optimal</b>	53.85%	42.02%	45.38%	33.40%
<b>2008</b>	<b>Acute Shock No Acute Shock</b>		<b>Premium Shock No Premium Shock</b>	
<b>% Pre-ICL Coverage</b>	75.94%	70.92%	72.56%	66.97%
<b>% ICL Coverage</b>	41.69%	28.51%	32.82%	18.16%
<b>Premium</b>	31.84	29.76	29.07	32.97
<b>% Within 25% of Optimal</b>	56.55%	46.13%	48.70%	40.92%

More ICL coverage

lower premiums

More ICL coverage



Yale SCHOOL OF  
MANAGEMENT

# First stage: decision to switch

Aggregate shock:

$$v_{it} = v_{ipt} + v_{ict} + v_{iht} + v_{iet}$$

Switch if

$$v_{it} > \bar{v}_i$$

The switching threshold varies at the individual level, estimated with demographics and health status (drug consumption)





Yale SCHOOL OF  
MANAGEMENT

# Second stage: to what plan?

First, utility from a plan

$$u_{ijt} = x_{ijt}\beta_1 + x_{ijt}v_{ipt}\beta_2 + x_{ijt}v_{iht}\beta_3 + x_{ijt}v_{ict}\beta_4 + \varepsilon_{ijt}$$

Utility depends on consumer characteristics as usual but may also depend on the type of shock.

No risk aversion. No learning.

X: oop costs, premium, deductible, coverage rates, national plan, enhanced plan, brand indicators

$\varepsilon_{ijt}$  distributed EV(1)



Yale SCHOOL OF  
MANAGEMENT

# Likelihood function

$j \neq k$  probability of searching and then choosing plan  $k$

$$X_{ijc}\theta_c - \log(1 + e^{X_{iks}\theta_s}) - \log\left(\sum_m e^{X_{imc}\theta_c}\right)$$

$j = k$  probability of not searching plus the probability of searching and choosing  $k$

$$\log(e^{X_{iks}\theta_s} \sum_m e^{X_{imc}\theta_c} + e^{X_{ikc}\theta_c}) - \log(1 + e^{X_{iks}\theta_s}) - \log\left(\sum_m e^{X_{imc}\theta_c}\right)$$



Yale SCHOOL OF  
MANAGEMENT

# Estimation

- TBD!
- Hoped to have results by today but we are still working on it.
- Parameters will let us calculate elasticities of demand
- Also quantify weights that consumers put on attributes



Yale SCHOOL OF  
MANAGEMENT

# Insurer optimizes

- Assume insurers are profit-maximizing
- What would we expect them to do in response to consumers?
  - Raise price slowly every period so as to create no shocks
  - Create premium/coverage shock only when loss of consumers offsets gain
  - Create generous plan to attract consumers who just experienced coverage or health shock
  - Create low-premium plan to attract consumers who just experience premium shock when gain offsets low price



# Premiums increase

**Table 19: Average Premium Increases**

	Premium Increase		% \$10 Increase		
	Basic	Enhanced	Basic	Enhanced	
<b>2007</b>	-0.35	4.97	2007	1.66%	17.64%
<b>2008</b>	2.87	5.33	<b>2008</b>	18.28%	32.71%
<b>2009</b>	4.90	7.63	<b>2009</b>	18.49%	37.46%
<b>2010</b>	2.52	3.96	<b>2010</b>	11.36%	16.09%
<b>2011</b>	-0.71	8.97	<b>2011</b>	7.01%	70.51%



# Enhanced plans enter

**Table 16: Entry and Exit of Enhanced Plans**

	<b># Plans</b>	<b>% Enhanced</b>	<b>Basic Entrants</b>	<b>Enhanced Entrants</b>	<b>Basic Exit</b>	<b>Enhanced Exit</b>
<b>2006</b>	1426	42.50%	-	-	78	143
<b>2007</b>	1866	47.53%	375	286	84	160
<b>2008</b>	1824	50.71%	84	118	57	148
<b>2009</b>	1687	52.82%	66	2	99	119
<b>2010</b>	1576	50.44%	33	74	216	280
<b>2011</b>	1109	45.27%	22	7	-	-



Yale SCHOOL OF  
MANAGEMENT

# Entrants undercut w/premium

**Table 17: Average Characteristics of Entrant Plans**

	Premium		Formulary Size		Tier-1 Top Drugs	
	Entrant	Incumbent	Entrant	Incumbent	Entrant	Incumbent
<b>Basic Plans</b>						
<b>2007</b>	23.47	24.06	742.69	851.44	36.57	48.64
<b>2008</b>	21.15	26.96	889.33	958.40	68.42	67.46
<b>2009</b>	26.39	30.96	875.46	990.24	70.09	69.00
<b>2010</b>	28.60	33.66	1016.56	1002.72	68.69	68.49
<b>2011</b>	16.54	33.52	1018.96	1001.99	26.53	59.28
<b>Enhanced Plans</b>						
<b>2007</b>	55.37	39.43	766.64	873.60	47.77	49.31
<b>2008</b>	34.85	41.06	871.83	962.91	66.69	67.54
<b>2009</b>	40.10	45.88	911.00	980.85	69.00	65.32
<b>2010</b>	31.14	50.05	1031.90	973.27	68.11	66.34
<b>2011</b>	84.23	62.57	939.08	1055.96	64.93	49.64



Yale SCHOOL OF  
MANAGEMENT

# Who creates premium shock?

**Table 20: Probit Regressions on \$10  
Premium Increase**

	<b>Basic Plans</b>	<b>Enhanced Plans</b>
<b>Lagged Minimum Cost Plan</b>	0.4752894*** (0.1491831)	-0.6232133*** (0.1819825)
<b>Market Below Plan Premium</b>	-0.6781189*** (0.1517455)	-0.0286261 (0.1125818)
<b>2006 Enrollment</b>	-0.0476587*** (0.0178041)	0.0013921 (0.0155525)
<b>% LIS Enrollment</b>	-0.8892201*** (0.1489461)	- -
<b>National Plan</b>	-0.2500414** (0.1108801)	-0.3455039*** (0.1205939)
<b>Constant</b>	0.1913813 (0.2440116)	-0.19232 (0.1920756)
<b>N</b>	2226	2568
<b>R<sup>2</sup></b>	0.0463	0.0076





# Who increases coverage?

**Table 21: Regressions on Change in % of  
Top Drugs Covered**

	<b>Basic Plans</b>	<b>Enhanced Plans</b>
<b>National Plan</b>	-3.331616** (1.509137)	1.343002 (2.109799)
<b>Lagged % of Market Below Plan Premium</b>	3.227054* (1.681067)	14.61257 (1.874321)
<b>Lagged Minimum Cost Plan</b>	4.588222** (2.163508)	27.28965*** (2.519987)
<b>2006 Enrollment</b>	0.1446073 (0.2023322)	-0.1179206 (0.2635939)
<b>Constant</b>	14.27138*** (2.371712)	-2.387997 (3.320813)
<b>N</b>	2115	2362
<b>R<sup>2</sup></b>	0.0059	0.0561



Yale SCHOOL OF  
MANAGEMENT

# Who drops premium significantly?

**Table 22: Probit Regressions on  
\$10 Premium Decrease**

	Basic Plans	Enhanced Plans
<b>National Plan</b>	-0.4867641*** (0.1310947)	0.1966372 (0.2281644)
<b>2006 Enrollment of Market Below Plan</b>	-0.1858255*** (0.0250658)	-0.1828018*** (0.0237597)
<b>% LIS Enrollment</b>	3.062852*** (0.3335822)	1.642915*** (0.2059287)
<b>Constant</b>	-0.0320105 (0.1818715)	-
	-2.353985*** (0.4004507)	-1.635561*** (0.3308937)

<b>N</b>	2226	2568
<b>R<sup>2</sup></b>	0.2802	0.0092



Yale SCHOOL OF  
MANAGEMENT

# Further work

- These are preliminary results
  - Demand estimation not complete
  - Analysis of national data will be improved
- But in existing results can see the consumer search behavior and the insurer response
- We want to quantify this more precisely



Yale SCHOOL OF  
MANAGEMENT

# Conclusions

- Consumers are not searching often or effectively
- It might be possible to fix behavior with a larger financial incentive
- But a financial incentive conflicts
  - with purpose of insurance
  - with subsidies for low income
- Example: reduction in financial incentive, filling the coverage gap -- will increase usage, reduce shocks to expenditure, reduce search
- Dollar amounts at stake in ACA are much larger